Adc Therapeutics SA (NYSE: ADCT) kicked off on Monday, down -5.37% from the previous trading day, before settling in for the closing price of $1.49. Over the past 52 weeks, ADCT has traded in a range of $1.39-$5.38.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 70.77% over the past five years. While this was happening, its average annual earnings per share was recorded 0.21%. With a float of $77.81 million, this company’s outstanding shares have now reached $98.86 million.
Let’s look at the performance matrix of the company that is accounted for 265 employees. In terms of profitability, gross margin is 89.43%, operating margin of -195.42%, and the pretax margin is -234.07%.
Adc Therapeutics SA (ADCT) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Adc Therapeutics SA is 21.47%, while institutional ownership is 55.35%. The most recent insider transaction that took place on Dec 11 ’24, was worth 304,500. In this transaction 10% Owner of this company bought 100,000 shares at a rate of $3.04, taking the stock ownership to the 15,666,731 shares. Before that another transaction happened on Dec 11 ’24, when Company’s 10% Owner bought 100,000 for $3.04, making the entire transaction worth $304,500. This insider now owns 13,145,712 shares in total.
Adc Therapeutics SA (ADCT) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 0.21% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.25% during the next five years compared to 1.38% growth over the previous five years of trading.
Adc Therapeutics SA (NYSE: ADCT) Trading Performance Indicators
Take a look at Adc Therapeutics SA’s (ADCT) current performance indicators. Last quarter, stock had a quick ratio of 3.59. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.97.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.66, a number that is poised to hit -0.40 in the next quarter and is forecasted to reach -1.35 in one year’s time.
Technical Analysis of Adc Therapeutics SA (ADCT)
Adc Therapeutics SA (NYSE: ADCT) saw its 5-day average volume 0.39 million, a negative change from its year-to-date volume of 0.46 million. As of the previous 9 days, the stock’s Stochastic %D was 22.28%. Additionally, its Average True Range was 0.13.
During the past 100 days, Adc Therapeutics SA’s (ADCT) raw stochastic average was set at 5.88%, which indicates a significant decrease from 20.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.00% in the past 14 days, which was lower than the 134.86% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.6646, while its 200-day Moving Average is $2.5282. Nevertheless, the first resistance level for the watch stands at $1.4833 in the near term. At $1.5567, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.6583. If the price goes on to break the first support level at $1.3083, it is likely to go to the next support level at $1.2067. The third support level lies at $1.1333 if the price breaches the second support level.
Adc Therapeutics SA (NYSE: ADCT) Key Stats
The company with the Market Capitalisation of 139.71 million has total of 96,690K Shares Outstanding. Its annual sales at the moment are 69,560 K in contrast with the sum of -240,050 K annual income. Company’s last quarter sales were recorded 18,460 K and last quarter income was -43,970 K.
